Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
This study has been completed.
Study NCT01586364 Information provided by Shionogi Inc.
First Received on April 18, 2012. Last Updated on May 21, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Genital Diseases, Female
Pathological Conditions, Anatomical
Interventions listed in this trial
Sponsors listed in this trial
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers